Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $25.00. On average, they predict the company's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.

Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 37.9% and is now trading at $11.55.
View the best growth stocks for 2023 here.

Catalyst Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 9,490,000 shares, a decline of 15.2% from the April 30th total of 11,190,000 shares. Based on an average daily volume of 1,920,000 shares, the short-interest ratio is presently 4.9 days. Currently, 9.6% of the company's shares are sold short.
View Catalyst Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our CPRX earnings forecast.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Wednesday, March, 15th. The biopharmaceutical company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.01. The biopharmaceutical company earned $60.76 million during the quarter, compared to the consensus estimate of $60.64 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 34.72% and a net margin of 38.76%.

ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Aztlan Global Stock Selection DM SMID ETF (AZTD), Innovator IBD 50 ETF (FFTY), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), ALPS Medical Breakthroughs ETF (SBIO) and Invesco S&P SmallCap Momentum ETF (XSMO).

Catalyst Pharmaceuticals updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $375.00 million-$385.00 million, compared to the consensus revenue estimate of $381.54 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.54%), State Street Corp (7.11%), Dimensional Fund Advisors LP (2.25%), Geode Capital Management LLC (1.75%), Two Sigma Advisers LP (1.49%) and Jupiter Asset Management Ltd. (1.35%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $11.55.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.23 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $0.88 on an earnings per share basis.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.